Newron Pharmaceuticals Successfully Completes Pilot Study of Safinamide in Restless Legs Syndrome
Advertisement
Newron Pharmaceuticals SpA, a research and development company focused on novel CNS therapies, announced that treatment with its investigational new drug, safinamide, resulted in a significant improvement in all efficacy parameters studied when administered to patients with restless legs syndrome (RLS). Safinamide was also found to be well tolerated and did not exhibit any clinically relevant side-effects. RLS is a neurological disorder, characterized by jerky movements of the lower extremities which appear mostly in the evening and during sleep.
RLS is a growing neurological condition affecting approximately 5% of the adult population in the US and EU. It is characterized by jerky movements or an uncomfortable, often painful, sensation in the lower extremities that mostly appear in the evening, at rest and during sleep. RLS is commonly associated with frequent awakenings at night and somnolence during the day, thus negatively affecting a patient's quality of life. In many cases, RLS can lead to bouts of depression and in some, suicide.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Kill the cancer, not the patient: New toxicity testing approach could make chemo drugs safer - National Cancer Institute grants $1M to test 3 chemo drugs
Pioneering discovery of an odor-detecting receptor enhancer
Modified crops reveal hidden cost of resistance
MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program - First HuCAL-based Antibody to Enter Clinical Trial in Second Indication
Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize
New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future
New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction
Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe
Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim
UF study strengthens concerns about long-term use of certain painkillers
Scientists at Almac and Queen’s University Belfast discover novel approach to treat cancer patients.
